Bush Jennifer sold $35K of ARTV

Bush Jennifer (COO, CLO, Compliance Officer) sold 8,439 shares of Artiva Biotherapeutics, Inc. (ARTV) at $4.18 on 2026-11-02.

Original reporting
SEC EDGAR · Bush Jennifer
Published Nov 3, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The insider sale is small and unlikely to move the stock significantly.

02

Market read

Limited relevance; minor insider transaction.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

SEC Form 4 filing by Artiva Biotherapeutics COO reporting a modest share sale.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Form 4 shows COO Jennifer Bush sold 8,439 shares for $35,284, a small insider sale.

Expected impact

likely modest downward pressure as market prices the sale.

Evidence & confidence

Sale size is small relative to holdings and market cap; impact limited.

Market effects

None significant for biotech sector.

No regional impact.

Minimal.

Counterpoint

The sale could be routine and not indicate negative sentiment.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm listed on NASDAQ under ARTV.

  • Jennifer Bush

    COO, CLO, Compliance Officer of Artiva.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.